Logo image of AYJ.DE

VALNEVA SE (AYJ.DE) Stock Fundamental Analysis

FRA:AYJ - Deutsche Boerse Ag - FR0004056851 - Common Stock - Currency: EUR

3.322  -0.18 (-5.03%)

Fundamental Rating

3

Taking everything into account, AYJ scores 3 out of 10 in our fundamental rating. AYJ was compared to 73 industry peers in the Biotechnology industry. AYJ has a bad profitability rating. Also its financial health evaluation is rather negative. AYJ is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

AYJ had negative earnings in the past year.
AYJ had a negative operating cash flow in the past year.
In the past 5 years AYJ always reported negative net income.
In multiple years AYJ reported negative operating cash flow during the last 5 years.
AYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFAYJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

AYJ has a Return On Assets of 3.34%. This is amongst the best in the industry. AYJ outperforms 86.11% of its industry peers.
AYJ has a Return On Equity of 7.94%. This is amongst the best in the industry. AYJ outperforms 84.72% of its industry peers.
Industry RankSector Rank
ROA 3.34%
ROE 7.94%
ROIC N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
AYJ.DE Yearly ROA, ROE, ROICAYJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

AYJ has a Profit Margin of 7.53%. This is amongst the best in the industry. AYJ outperforms 86.11% of its industry peers.
AYJ has a Gross Margin (38.74%) which is in line with its industry peers.
In the last couple of years the Gross Margin of AYJ has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 7.53%
GM 38.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
AYJ.DE Yearly Profit, Operating, Gross MarginsAYJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

AYJ does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AYJ has more shares outstanding
The number of shares outstanding for AYJ has been increased compared to 5 years ago.
The debt/assets ratio for AYJ is higher compared to a year ago.
AYJ.DE Yearly Shares OutstandingAYJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
AYJ.DE Yearly Total Debt VS Total AssetsAYJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

AYJ has an Altman-Z score of -0.02. This is a bad value and indicates that AYJ is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.02, AYJ is in line with its industry, outperforming 51.39% of the companies in the same industry.
AYJ has a Debt/Equity ratio of 0.82. This is a neutral value indicating AYJ is somewhat dependend on debt financing.
AYJ has a Debt to Equity ratio (0.82) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Altman-Z -0.02
ROIC/WACCN/A
WACC7.95%
AYJ.DE Yearly LT Debt VS Equity VS FCFAYJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 2.78 indicates that AYJ has no problem at all paying its short term obligations.
AYJ has a better Current ratio (2.78) than 63.89% of its industry peers.
A Quick Ratio of 2.25 indicates that AYJ has no problem at all paying its short term obligations.
AYJ has a Quick ratio of 2.25. This is comparable to the rest of the industry: AYJ outperforms 54.17% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.25
AYJ.DE Yearly Current Assets VS Current LiabilitesAYJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

AYJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.90%, which is quite impressive.
Looking at the last year, AYJ shows a very negative growth in Revenue. The Revenue has decreased by -44.52% in the last year.
The Revenue has been growing slightly by 6.34% on average over the past years.
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%

3.2 Future

The Earnings Per Share is expected to grow by 36.05% on average over the next years. This is a very strong growth
AYJ is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.69% yearly.
EPS Next Y100.62%
EPS Next 2Y14.98%
EPS Next 3Y18.66%
EPS Next 5Y36.05%
Revenue Next Year8.62%
Revenue Next 2Y7.96%
Revenue Next 3Y13.76%
Revenue Next 5Y22.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AYJ.DE Yearly Revenue VS EstimatesAYJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
AYJ.DE Yearly EPS VS EstimatesAYJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AYJ. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AYJ. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AYJ.DE Price Earnings VS Forward Price EarningsAYJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AYJ.DE Per share dataAYJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AYJ's earnings are expected to grow with 18.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.98%
EPS Next 3Y18.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AYJ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

FRA:AYJ (3/7/2025, 7:00:00 PM)

3.322

-0.18 (-5.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners29.31%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap269.74M
Analysts83.08
Price Target7.56 (127.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.09%
Min EPS beat(2)-44.01%
Max EPS beat(2)52.2%
EPS beat(4)2
Avg EPS beat(4)9.65%
Min EPS beat(4)-44.01%
Max EPS beat(4)72.74%
EPS beat(8)4
Avg EPS beat(8)-33.8%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.31%
Min Revenue beat(2)-14.39%
Max Revenue beat(2)1.77%
Revenue beat(4)1
Avg Revenue beat(4)-8.04%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)1.77%
Revenue beat(8)5
Avg Revenue beat(8)25.47%
Revenue beat(12)7
Avg Revenue beat(12)131.76%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.24%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)122.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)-1.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.18
P/FCF N/A
P/OCF N/A
P/B 1.24
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-2.08
FCFYN/A
OCF(TTM)-1.76
OCFYN/A
SpS2.82
BVpS2.68
TBVpS2.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 3.34%
ROE 7.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 7.53%
GM 38.74%
FCFM N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.82
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.88%
Cap/Sales 11.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.25
Altman-Z -0.02
F-Score3
WACC7.95%
ROIC/WACCN/A
Cap/Depr(3y)291.07%
Cap/Depr(5y)239.89%
Cap/Sales(3y)14.73%
Cap/Sales(5y)14.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
EPS Next Y100.62%
EPS Next 2Y14.98%
EPS Next 3Y18.66%
EPS Next 5Y36.05%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%
Revenue Next Year8.62%
Revenue Next 2Y7.96%
Revenue Next 3Y13.76%
Revenue Next 5Y22.69%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year160.39%
EBIT Next 3Y30.6%
EBIT Next 5Y25.83%
FCF growth 1Y20.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.38%
OCF growth 3YN/A
OCF growth 5YN/A